Home  |  Contact

UniProtKB/Swiss-Prot P42771: Variant p.Val126Asp

Cyclin-dependent kinase inhibitor 2A
Gene: CDKN2A
Variant information

Variant position:  126
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Valine (V) to Aspartate (D) at position 126 (V126D, p.Val126Asp).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (V) to medium size and acidic (D)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CMM2; impairs the function.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.

Sequence information

Variant position:  126
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  156
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         VRDAWGRLPVDLAEELGHRDVARYLR-------------AAAGGTRG--------SNHARID


Rat                           VRDAWGRLPLDLALERGHHDVVRYLR----------YLLSS

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 1 – 156 Cyclin-dependent kinase inhibitor 2A
Repeat 110 – 139 ANK 4
Modified residue 140 – 140 Phosphoserine
Alternative sequence 117 – 156 Missing. In isoform 3.
Helix 124 – 130

Literature citations

Germline p16 mutations in familial melanoma.
Hussussian C.J.; Struewing J.P.; Goldstein A.M.; Higgins P.A.T.; Ally D.S.; Sheahan M.D.; Clark W.H. Jr.; Tucker M.A.; Dracopoli N.C.;
Nat. Genet. 8:15-21(1994)
Cited for: VARIANTS CMM2 PRO-87; TRP-101 AND ASP-126; VARIANTS THR-49; SER-71 AND THR-148;

Mutations associated with familial melanoma impair p16INK4 function.
Ranade K.; Hussussian C.J.; Sikorski R.S.; Varmus H.E.; Goldstein A.M.; Tucker M.A.; Serrano M.; Hannon G.J.; Beach D.; Dracopoli N.C.;
Nat. Genet. 10:114-116(1995)

A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.
Goldstein A.M.; Liu L.; Shennan M.G.; Hogg D.; Tucker M.A.; Struewing J.P.;
Br. J. Cancer 85:527-530(2001)
Cited for: VARIANT CMM2 ASP-126;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.